Health
Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian
Australian company applies for permission to conduct trial of men and women aged 18 to 55
Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…
-
General19 hours agoTributes flow after Australian Paralympic bronze medallist Nicholas Hum dies aged 32
-
General14 hours agoReuven Morrison was killed in the Bondi Beach shooting one year after warning about antisemitism
-
General15 hours agoNT’s top year 12 achievers celebrated, with some looking to pursue teaching careers
-
Noosa News12 hours agoQueensland coroner investigates ‘extremely unusual’ deaths of premature twin boys